Non-Invasive Diagnostic System Based on Light for Detecting Early-Stage Oral Cancer and High-Risk Precancerous Lesions-Potential for Dentistry

被引:13
|
作者
Tatehara, Seiko [1 ]
Satomura, Kazuhito [1 ]
机构
[1] Tsurumi Univ, Sch Dent Med, Dept Oral Med & Stomatol, Tsurumi Ku, 2-1-3 Tsurumi, Yokohama, Kanagawa 2308501, Japan
关键词
chemiluminescence; autofluorescence; photodynamic diagnosis (PDD); oral cancer; oral epithelial dysplasia (OED); oral potentially malignancy disorders (OPMDs); protoporphyrin IX; fluorescence; INDUCED PROTOPORPHYRIN-IX; 5-ALA-INDUCED PPIX FLUORESCENCE; 5-AMINOLEVULINIC ACID; MALIGNANT-TRANSFORMATION; EPITHELIAL DYSPLASIA; TOLUIDINE BLUE; PHOTODYNAMIC THERAPY; TOPICAL APPLICATION; CLINICAL-EVALUATION; NEOPLASTIC LESIONS;
D O I
10.3390/cancers12113185
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary The early detection of oral cancer and oral potentially malignant disorders can facilitate minimum intervention and subsequent improvements in prognosis and quality of life after treatment. Recently, several non-invasive adjunctive fluorescence-based detection systems have improved the accuracy of detection and diagnosis of oral cancer and oral potentially malignant disorders. This article summarizes current knowledge about fluorescence-based diagnostic methods and discusses their benefits and drawbacks from a clinical viewpoint. Oral health promotion and examinations have contributed to the early detection of oral cancer and oral potentially malignant disorders, leading to the adaptation of minimally invasive therapies and subsequent improvements in the prognosis/maintenance of the quality of life after treatments. However, the accurate detection of early-stage oral cancer and oral epithelial dysplasia is particularly difficult for conventional oral examinations because these lesions sometimes resemble benign lesions or healthy oral mucosa tissues. Although oral biopsy has been considered the gold standard for accurate diagnosis, it is deemed invasive for patients. For this reason, most clinicians are looking forward to the development of non-invasive diagnostic technologies to detect and distinguish between cancerous and benign lesions. To date, several non-invasive adjunctive fluorescence-based detection systems have improved the accuracy of the detection and diagnosis of oral mucosal lesions. Autofluorescence-based systems can detect lesions as a loss of autofluorescence through irradiation with blue-violet lights. Photodynamic diagnosis using 5-aminolevulinic acid (ALA-PDD) shows the presence of very early oral cancers and oral epithelial dysplasia as a red fluorescent area. In this article, currently used fluorescence-based diagnostic methods are introduced and discussed from a clinical point of view.
引用
收藏
页码:1 / 15
页数:15
相关论文
共 50 条
  • [41] Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
    Yeung, Kay T.
    Kalinsky, Kevin
    Yau, Christina
    Chien, Amy Jo
    Boughey, Judy Caroline
    Stringer-Reasor, Erica Michelle
    Falkson, Carla Isadora
    Albain, Kathy S.
    Mayer, Ingrid A.
    Trivedi, Meghna S.
    Nanda, Rita
    Douglas, Emily H.
    Omene, Coral Oghenerukevwe
    Rugo, Hope S.
    Isaacs, Claudine
    Parker, Beverly
    DeMichele, Angela
    Yee, Douglas
    Esserman, Laura
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA520 - LBA520
  • [42] Incidence of High-Risk Radiologic Features in Patients Without Local Recurrence After Stereotactic Ablative Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer
    Ronden, M. I.
    van Sornsen de Koste, J. R.
    Johnson, C.
    Slotman, B. J.
    Spoelstra, F. O. B.
    Haasbeek, C. J. A.
    Blom, G.
    Bongers, E. M.
    Warner, A.
    Ward, A.
    Palma, D.
    Senan, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 100 (01): : 115 - 121
  • [43] Validation of High-Risk Computed Tomography Features for Detection of Local Recurrence After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer
    Peulen, Heike
    Mantel, Frederick
    Guckenberger, Matthias
    Belderbos, Jose
    Werner-Wasik, Maria
    Hope, Andrew
    Giuliani, Meredith
    Grills, Inga
    Sonke, Jan-Jakob
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (01): : 134 - 141
  • [44] A Phase II Study of Stereotactic Body Radiotherapy and Stereotactic Body Proton Therapy for High-Risk Medically Inoperable Early-Stage Non-Small Cell Lung Cancer
    Chang, Joe Y.
    Nantavithya, Chonnipa
    Gomez, Daniel R.
    Komaki, Ritsuko
    Liao, Zhongxing
    Wei, Xiong
    Lin, Steven H.
    Jeter, Melenda
    Quynh-Nhu Nguyen
    Li, Heng
    Zhang, Xiaodong
    Poenisch, Falk
    Zhu, X. Ronald
    Balter, Peter A.
    Mohan, Radhe
    Feng, Lei
    Choi, Noah C.
    Chang, Joe Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 101 (02): : E2 - E2
  • [45] The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: An exploratory analysis of a Gynecologic Oncology Group study
    Chan, John K.
    Tian, Chunqiao
    Fleming, Gini F.
    Monk, Bradley J.
    Herzog, Thomas J.
    Kapp, Daniel S.
    Bell, Jeffrey
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : 301 - 306
  • [46] Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.
    Yeung, Kay T.
    Kalinsky, Kevin
    Yau, Christina
    Chien, Amy Jo
    Boughey, Judy Caroline
    Stringer-Reasor, Erica Michelle
    Falkson, Carla Isadora
    Albain, Kathy S.
    Mayer, Ingrid A.
    Trivedi, Meghna S.
    Nanda, Rita
    Douglas, Emily H.
    Omene, Coral Oghenerukevwe
    Rugo, Hope S.
    Isaacs, Claudine
    Parker, Beverly
    DeMichele, Angela
    Yee, Douglas
    Esserman, Laura
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
  • [47] Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer
    Nantavithya, Chonnipa
    Gomez, Daniel R.
    Wei, Xiong
    Komaki, Ritsuko
    Liao, Zhongxing
    Lin, Steven H.
    Jeter, Melenda
    Quynh-Nhu Nguyen
    Li, Heng
    Zhang, Xiaodong
    Poenisch, Falk
    Zhu, X. Ronald
    Balter, Peter A.
    Feng, Lei
    Choi, Noah C.
    Mohan, Radhe
    Chang, Joe Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 101 (03): : 558 - 563
  • [48] The need for a second transurethral resection in high-risk non-muscle-invasive bladder cancer based on the Vesicle Imaging-Reporting and Data System
    Nakamura, Yuki
    Yoshida, Soichiro
    Arita, Yuki
    Takeshita, Ryo
    Kimura, Koichiro
    Kobayashi, Masaki
    Fujiwara, Motohiro
    Ishikawa, Yudai
    Fukuda, Shohei
    Waseda, Yuma
    Tanaka, Hajime
    Jinzaki, Masahiro
    Fujii, Yasuhisa
    INTERNATIONAL JOURNAL OF UROLOGY, 2025, 32 (03) : 264 - 269
  • [49] A Phase II Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-risk Medically Inoperable Early-stage Non-small Cell Lung Cancer
    Hurmuz, Pervin
    Ozyigit, Gokhan
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 101 (03): : 744 - 745
  • [50] A Phase II Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-risk Medically Inoperable Early-stage Non-small Cell Lung Cancer Reply
    Chang, Joe Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 101 (03): : 745 - 745